drugset / Trial / NCT00325364

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

NCT00325364

Phase 3 Completed 415 enrolled Eli Lilly and Company Alkermes, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 2 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.

Timeline

Start
2006-04
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled
Comparator Insulin Lispro Protein / enzyme biologic Other